Welcome! Login | Register
 

Finneran: She Once Was Mine—Finneran: She Once Was Mine

Friday Financial Five – June 23, 2017—Friday Financial Five – June 23, 2017

Celtics Select Duke’s Tatum With #3 Overall Pick in NBA Draft—Celtics Select Duke's Tatum With #3 Overall Pick…

MassFiscal Poll Shows Legislative Pay Raise Unpopular With Voters—MassFiscal Poll Shows Legislative Pay Raise Unpopular With…

Bronx Man Arrested for Trafficking Heroin in Worcester—Bronx Man Arrested for Trafficking Heroin in Worcester

Worcester Ranked Among Worst Cities to Raise a Family in MA—Worcester Ranked Among Worst Cities to Raise a…

Fecteau: Democrats Lose Again—Fecteau: Democrats Lose Again

Worcester County Food Bank Working to Grow Breakfast in Classroom Programs—Worcester County Food Bank Working to Grow Breakfast…

Where Will You WOO? - Week of June 22, 2017—Where Will You WOO? - Week of June…

Red Sox Bullpen Can’t Hold Lead, Fall 6-4 to Kansas City—Red Sox Bullpen Can't Hold Lead, Fall 6-4…

 
 

AG Announces $68.5 Million Settlement with AstraZeneca

Friday, March 11, 2011

 

Attorney General Peter Kilmartin announced today that a $68.5 million dollar settlement has been reached with AstraZeneca Pharmaceuticals.

This settlement, which is the largest ever multi-state consumer protection-based pharmaceutical settlement, is expected to bring $908,838 to the state.

The settlement stems from a complaint alleging that AstraZeneca used deceptive practices to market the antipsychotic drug Seroquel for off-label uses, according to the Attorney General. The company was accused of withholding information on the drug’s dangerous potential side effects, in addition to the negative results of scientific study done that tested the safety of the drug.

“This settlement shows the commitment of this office to protect consumers from deceptive marketing and advertising practices by big pharmaceutical companies,” Kilmartin said.

Company promises changes

AstraZeneca has promised to alter the way that it markets Seroquel, eliminating the misleading practices in question. Along with the $68.5 million payment, under the settlement AstraZeneca must comply with provisions addressing numerous concerns that an extensive 3-year investigation yielded. For example, AstraZeneca must have policies in place to ensure that sales personnel do not promote to health care providers who are unlikely to prescribe Seroquel for an FDA-approved use.

Other states participating in the investigation and settlement were: Florida, Illinois, Arizona, California, Colorado, Connecticut, Delaware, Hawaii, Idaho, Iowa, Kansas, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, West Virginia and Wisconsin.
 

 

Enjoy this post? Share it with others.

 
Delivered Free Every
Day to Your Inbox